Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vericat

Showing results (181-190 of 191) with videos related to

Pageof 20
Sort By:
Thrombosis Research|June 13, 2022
Pharmacokinetic and clinical improvements after PK-guided switch from standard half-life to extended half-life factor VIII productsJ E Megías-Vericat, S Bonanad Boix, R Berrueco Moreno, et al.
Leukemia & Lymphoma|June 14, 2021
Evolving patterns of care and outcomes in relapsed/refractory FLT3 mutated acute myeloid leukemia adult patientsBlanca Boluda, David Martínez-Cuadrón, Lorenzo Algarra, et al.
European Journal of Clinical Pharmacology|August 30, 2025
Validation of pharmacokinetic model for quizartinib quantified by UPLC-MS/MS in patients with FLT3-ITD negative newly diagnosed acute myeloid leukemiaAntonio Solana-Altabella, Carles Iniesta-Navalón, Maria Chovi-Trull, et al.
European Cardiology|November 13, 2018
Impact of an Integral Assistance on the Management of Patients with Chronic Heart DiseasesRomán Freixa-Pamias, Pere Blanch Gràcia, Lluïsa Rodriguez Latre, et al.
Cancers|May 16, 2023
Incidence and Risk Factors for Development of Cardiac Toxicity in Adult Patients with Newly Diagnosed Acute Myeloid LeukemiaBlanca Boluda, Antonio Solana-Altabella, Isabel Cano, et al.
Mediterranean Journal of Hematology and Infectious Diseases|March 13, 2019
Differences in <i>ex-vivo</i> Chemosensitivity to Anthracyclines in First Line Acute Myeloid LeukemiaJuan Eduardo Megías-Vericat, David Martínez-Cuadrón, Joaquín Martínez López, et al.
Alternatives to Laboratory Animals : ATLA|March 9, 2006
Metabolism: a bottleneck in in vitro toxicological test development. The report and recommendations of ECVAM workshop 54Sandra Coecke, Hans Ahr, Bas J Blaauboer, et al.
Haematologica|May 18, 2023
Outcomes after intensive chemotherapy for secondary and myeloid-related changes acute myeloid leukemia patients aged 60 to 75 years old: a retrospective analysis from the PETHEMA registryDavid Martínez-Cuadrón, Juan E Megías-Vericat, Cristina Gil, et al.
Blood Advances|November 18, 2021
Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry studyDavid Martínez-Cuadrón, Juan E Megías-Vericat, Josefina Serrano, et al.
Clinical and Experimental Rheumatology|December 18, 2025
Immunological signatures in patients with Sjögren's disease: association with systemic disease activity at diagnosisLucía Delgado, Alejandra Flores-Chávez, Antónia Szántó, et al.
Pageof 20

Showing results (181-190 of 191) with videos related to

Sort By:
Pageof 20
Thrombosis Research|June 13, 2022
Pharmacokinetic and clinical improvements after PK-guided switch from standard half-life to extended half-life factor VIII productsJ E Megías-Vericat, S Bonanad Boix, R Berrueco Moreno, et al.
Leukemia & Lymphoma|June 14, 2021
Evolving patterns of care and outcomes in relapsed/refractory FLT3 mutated acute myeloid leukemia adult patientsBlanca Boluda, David Martínez-Cuadrón, Lorenzo Algarra, et al.
European Journal of Clinical Pharmacology|August 30, 2025
Validation of pharmacokinetic model for quizartinib quantified by UPLC-MS/MS in patients with FLT3-ITD negative newly diagnosed acute myeloid leukemiaAntonio Solana-Altabella, Carles Iniesta-Navalón, Maria Chovi-Trull, et al.
European Cardiology|November 13, 2018
Impact of an Integral Assistance on the Management of Patients with Chronic Heart DiseasesRomán Freixa-Pamias, Pere Blanch Gràcia, Lluïsa Rodriguez Latre, et al.
Cancers|May 16, 2023
Incidence and Risk Factors for Development of Cardiac Toxicity in Adult Patients with Newly Diagnosed Acute Myeloid LeukemiaBlanca Boluda, Antonio Solana-Altabella, Isabel Cano, et al.
Mediterranean Journal of Hematology and Infectious Diseases|March 13, 2019
Differences in <i>ex-vivo</i> Chemosensitivity to Anthracyclines in First Line Acute Myeloid LeukemiaJuan Eduardo Megías-Vericat, David Martínez-Cuadrón, Joaquín Martínez López, et al.
Alternatives to Laboratory Animals : ATLA|March 9, 2006
Metabolism: a bottleneck in in vitro toxicological test development. The report and recommendations of ECVAM workshop 54Sandra Coecke, Hans Ahr, Bas J Blaauboer, et al.
Haematologica|May 18, 2023
Outcomes after intensive chemotherapy for secondary and myeloid-related changes acute myeloid leukemia patients aged 60 to 75 years old: a retrospective analysis from the PETHEMA registryDavid Martínez-Cuadrón, Juan E Megías-Vericat, Cristina Gil, et al.
Blood Advances|November 18, 2021
Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry studyDavid Martínez-Cuadrón, Juan E Megías-Vericat, Josefina Serrano, et al.
Clinical and Experimental Rheumatology|December 18, 2025
Immunological signatures in patients with Sjögren's disease: association with systemic disease activity at diagnosisLucía Delgado, Alejandra Flores-Chávez, Antónia Szántó, et al.
Pageof 20